T. Rowe Price Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.58M | Buy |
|
|||||
|
2025
Q1 | $9.36M | Sell |
|
|||||
|
2024
Q4 | $38.9M | Sell |
|
|||||
|
2024
Q3 | $46.6M | Sell |
|
|||||
|
2024
Q2 | $81M | Sell |
|
|||||
|
2024
Q1 | $96.3M | Sell |
|
|||||
|
2023
Q4 | $155M | Buy |
|
|||||
|
2023
Q3 | $107M | Sell |
|
|||||
|
2023
Q2 | $112M | Sell |
|
|||||
|
2023
Q1 | $126M | Buy |
|
|||||
|
2022
Q4 | $96M | Buy |
|
|||||
|
2022
Q3 | $51.9M | Buy |
|
|||||
|
2022
Q2 | $43.5M | Sell |
|
|||||
|
2022
Q1 | $123M | Buy |
|
|||||
|
2021
Q4 | $108M | Buy |
|
|||||
|
2021
Q3 | $93.9M | Sell |
|
|||||
|
2021
Q2 | $139M | Sell |
|
|||||
|
2021
Q1 | $144M | Sell |
|
|||||
|
2020
Q4 | $181M | Buy |
|
|||||
|
2020
Q3 | $149M | Buy |
|
|||||
|
2020
Q2 | $178M | Buy |
|
|||||
|
2020
Q1 | $119M | Sell |
|
|||||
|
2019
Q4 | $179M | Sell |
|
|||||
|
2019
Q3 | $151M | Sell |
|
|||||
|
2019
Q2 | $197M | Sell |
|
|||||
|
2019
Q1 | $220M | Buy |
|
|||||
|
2018
Q4 | $194M | Sell |
|
|||||
|
2018
Q3 | $236M | Sell |
|
|||||
|
2018
Q2 | $238M | Buy |
|
|||||
|
2018
Q1 | $184M | Sell |
|
|||||
|
2017
Q4 | $216M | Buy |
|
|||||
|
2017
Q3 | $187M | Buy |
|
|||||
|
2017
Q2 | $149M | Buy |
|
|||||
|
2017
Q1 | $131M | Buy |
|
|||||
|
2016
Q4 | $98.7M | Sell |
|
|||||
|
2016
Q3 | $239M | Sell |
|
|||||
|
2016
Q2 | $274M | Sell |
|
|||||
|
2016
Q1 | $513M | Sell |
|
|||||
|
2015
Q4 | $841M | Buy |
|
|||||
|
2015
Q3 | $794M | Sell |
|
|||||
|
2015
Q2 | $1.09B | Sell |
|
|||||
|
2015
Q1 | $1.02B | Buy |
|
|||||
|
2014
Q4 | $175M | Sell |
|
|||||
|
2014
Q3 | $147M | Sell |
|
|||||
|
2014
Q2 | $134M | Sell |
|
|||||
|
2014
Q1 | $157M | Sell |
|
|||||
|
2013
Q4 | $188M | Sell |
|
|||||
|
2013
Q3 | $205M | Sell |
|
|||||
|
2013
Q2 | $164M | Buy |
|